 "Suven Life gets 2 product patents in US")
In a filing to the BSE on Wednesday, the company said that the granted claims of the patents included the class of selective 5-HT compounds discovered by Suven and were being developed as therapeutic agents.
These therapeutic agents are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's, attention deficient hyperactivity, Huntington's, Parkinson and Schizophrenia diseases, it added.
With these new patents, Suven now has 17 granted patents from the US, and products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II, the company said.
Suven Life Sciences' scrip is currently trading at Rs 72.30 on the BSE, up 1.54%, over the previous close of Rs 71.20 a share.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app